135 related articles for article (PubMed ID: 20723442)
1. [Expert consensus for the diagnosis and treatment of bone metastasis from prostate cancer].
Expert Group on the Diagnosis and Treatment of Bone Metastasis from Prostate Cancer
Zhonghua Zhong Liu Za Zhi; 2010 May; 32(5):396-8. PubMed ID: 20723442
[No Abstract] [Full Text] [Related]
2. [Therapeutic guidelines in prostate cancer and role for bisphosphonates in bone metastasis].
Miki T; Okihara K
Nihon Rinsho; 2007 Nov; 65 Suppl 9():632-5. PubMed ID: 18161177
[No Abstract] [Full Text] [Related]
3. Quality of life with advanced metastatic prostate cancer.
Resnick MJ; Penson DF
Urol Clin North Am; 2012 Nov; 39(4):505-15. PubMed ID: 23084527
[TBL] [Abstract][Full Text] [Related]
4. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
[TBL] [Abstract][Full Text] [Related]
5. Current status of treatment for patients with metastatic prostate cancer.
Higano CS
Can J Urol; 2005 Jun; 12 Suppl 2():38-41. PubMed ID: 16018832
[TBL] [Abstract][Full Text] [Related]
6. The role of bisphosphonates in the treatment of prostate cancer.
Parker CC
BJU Int; 2005 May; 95(7):935-8. PubMed ID: 15839907
[No Abstract] [Full Text] [Related]
7. Docetaxel and beyond.
Tombal B
Eur Urol; 2007 May; 51(5):1159-61. PubMed ID: 17229518
[No Abstract] [Full Text] [Related]
8. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.
Green JR
Acta Oncol; 2005; 44(3):282-92. PubMed ID: 16076701
[TBL] [Abstract][Full Text] [Related]
9. Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone.
Kikuno N; Urakami S; Nakamura S; Shiina H; Igawa M
Int J Urol; 2007 Jan; 14(1):82-4. PubMed ID: 17199867
[TBL] [Abstract][Full Text] [Related]
10. Bone complications: an increasing risk in patients with prostate cancer.
J Support Oncol; 2007 Feb; 5(2):88-9. PubMed ID: 17348369
[No Abstract] [Full Text] [Related]
11. Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.
Pouessel D; Culine S
Anticancer Drugs; 2012 Jan; 23(1):141-2. PubMed ID: 21934600
[TBL] [Abstract][Full Text] [Related]
12. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel.
Saad F; Higano CS; Sartor O; Colombel M; Murray R; Mason MD; Tubaro A; Schulman C
Clin Genitourin Cancer; 2006 Mar; 4(4):257-62. PubMed ID: 16729908
[TBL] [Abstract][Full Text] [Related]
13. Maintaining bone health in prostate cancer throughout the disease continuum.
Saad F; Eastham J
Semin Oncol; 2010 Jun; 37 Suppl 1():S30-7. PubMed ID: 20682370
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid (Zometa): bisphosphonate for prostate cancer/bone metastases.
Gaines KK
Urol Nurs; 2002 Dec; 22(6):398-400. PubMed ID: 12593231
[No Abstract] [Full Text] [Related]
15. Skeletal-related events in prostate cancer.
Smith MR
Clin Adv Hematol Oncol; 2012 Aug; 10(8):535-6. PubMed ID: 23073052
[No Abstract] [Full Text] [Related]
16. Management of androgen-independent prostate cancer.
Diaz M; Patterson SG
Cancer Control; 2004; 11(6):364-73. PubMed ID: 15625524
[TBL] [Abstract][Full Text] [Related]
17. [Complete androgen blockage in the treatment of metastatic prostate cancer].
Matzkin H; Braf Z
Harefuah; 1994 Mar; 126(5):260-3. PubMed ID: 8188104
[No Abstract] [Full Text] [Related]
18. [Treatment of prostate cancer].
Romics I
Orv Hetil; 2010 Apr; 151(14):580-3. PubMed ID: 20332076
[No Abstract] [Full Text] [Related]
19. Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency.
Breen TL; Shane E
J Clin Oncol; 2004 Apr; 22(8):1531-2. PubMed ID: 15084635
[No Abstract] [Full Text] [Related]
20. In focus: prostate cancer.
Clin Adv Hematol Oncol; 2003 May; 1(5):271. PubMed ID: 16235417
[No Abstract] [Full Text] [Related]
[Next] [New Search]
